Copyright
©The Author(s) 2024.
World J Gastroenterol. Feb 28, 2024; 30(8): 863-880
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.863
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.863
Figure 6 Nomogram for progression-free survival.
A: Nomogram for progression-free survival (PFS); B: One-year and 3-year area under the curves for PFS; C: Calibration curves for PFS; D: Decision curve analysis for PFS. AUC: Area under the curve; PFS: Progression-free survival; OS: Overall survival; ALP: Alkaline phosphatase; Eosi: Eosinophil count; CA724: Carbohydrate antigen 724; CA125: Carbohydrate antigen 125.
- Citation: Deng GM, Song HB, Du ZZ, Xue YW, Song HJ, Li YZ. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor. World J Gastroenterol 2024; 30(8): 863-880
- URL: https://www.wjgnet.com/1007-9327/full/v30/i8/863.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i8.863